OxThera announces completion of recruitment in Phase 3 ePHex study with Oxabact® in patients with primary hyperoxaluria
OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announced today that it has completed enrollment in its Oxabact ePHex phase III study. Oxabact is an investigational […]